enVVeno Medical (NASDAQ:NVNO) Given “Sell (D-)” Rating at Weiss Ratings

enVVeno Medical (NASDAQ:NVNO)‘s stock had its “sell (d-)” rating reiterated by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Several other analysts also recently issued reports on NVNO. LADENBURG THALM/SH SH downgraded enVVeno Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 21st. Wall Street Zen downgraded enVVeno Medical from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce”.

enVVeno Medical Stock Down 0.2%

NASDAQ NVNO opened at $0.96 on Wednesday. The stock’s 50-day moving average price is $1.96 and its 200-day moving average price is $3.02. enVVeno Medical has a 52 week low of $0.67 and a 52 week high of $5.62. The company has a market capitalization of $18.43 million, a P/E ratio of -0.80 and a beta of 0.94.

enVVeno Medical (NASDAQ:NVNO) last posted its quarterly earnings data on Thursday, July 31st. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05). Research analysts anticipate that enVVeno Medical will post -1.32 EPS for the current year.

Institutional Investors Weigh In On enVVeno Medical

Several hedge funds have recently made changes to their positions in NVNO. Jane Street Group LLC purchased a new stake in enVVeno Medical during the 2nd quarter valued at about $51,000. Creative Planning acquired a new stake in enVVeno Medical during the second quarter worth $54,000. XTX Topco Ltd acquired a new stake in enVVeno Medical during the first quarter worth $80,000. Dauntless Investment Group LLC purchased a new position in shares of enVVeno Medical during the first quarter worth $186,000. Finally, Westside Investment Management Inc. boosted its position in shares of enVVeno Medical by 26.4% during the first quarter. Westside Investment Management Inc. now owns 259,050 shares of the company’s stock worth $681,000 after buying an additional 54,025 shares during the period. 34.71% of the stock is currently owned by hedge funds and other institutional investors.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).